Cyclic Multi-Target Kinase Inhibitors for Blood-Brain Barrier Penetration

The patent applies universality by designing a single cyclic compound (Formula I) that can simultaneously inhibit multiple kinase targets including LRRK2, FGFR, and VEGFR. The molecular structure contains specific pharmacophore elements that enable broad kinase binding affinity, allowing one drug molecule to perform multiple therapeutic functions across different disease indications.

The patent employs parameter changes by systematically optimizing molecular properties such as lipophilicity, molecular weight, and hydrogen bond capacity to achieve blood-brain barrier penetration. The cyclic core structure with specific substituent patterns (R1-R6 groups) is designed to fine-tune physicochemical parameters that control BBB permeability while maintaining kinase inhibitory activity.

The patent applies local quality by differentiating functional regions within the cyclic molecule. The core cyclic structure provides BBB-penetrating properties through optimized lipophilicity and size, while specific substituent groups (R1-R6) attached at different positions provide kinase-specific binding interactions. This spatial separation of functions allows simultaneous achievement of BBB permeability and multi-kinase targeting.

The patent uses composite material principles by combining a cyclic core scaffold with multiple diverse substituent groups that confer different properties. The molecule integrates hydrophobic regions for membrane permeation with polar and aromatic regions for kinase active site binding, creating a composite molecular structure that achieves both BBB penetration and broad kinase inhibition.